New hope for back pain: higher dose of secukinumab tested in chinese ankylosing spondylitis patients
NCT ID NCT05303285
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a higher dose (300 mg) of the drug secukinumab (Cosentyx) can safely and effectively reduce symptoms in Chinese adults with active ankylosing spondylitis who have not gotten relief from at least two NSAIDs. One hundred participants will receive either 300 mg or 150 mg of secukinumab as an injection. The main goal is to see if more patients achieve a 40% improvement in disease activity after 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab (Cosentyx), a biologic drug given as an injection
What this could lead to
If successful, this could confirm that a higher dose of secukinumab (300 mg) is safe and effective for Chinese patients with ankylosing spondylitis who have not responded to standard treatments.
What could go wrong
This is a phase 4 study with a relatively small number of participants (100). The results may not apply to all patients, and there is always a risk of side effects such as infections or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS (AS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of RheumatologyTongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact